Long-term effects of fingolimod in multiple sclerosis
نویسندگان
چکیده
منابع مشابه
Benefit–Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis
Since the approval of fingolimod, several selective sphingosine-1-phosphate receptor modulators have entered clinical development for multiple sclerosis. However, side effects can occur with sphingosine-1-phosphate receptor modulators. By considering short-term data across the drug class and longer term fingolimod data, we aim to highlight the potential of sphingosine-1-phosphate receptor modul...
متن کاملOne-year Effectiveness and Side Effects of Fingolimod in Multiple Sclerosis Patients
Background and purpose: Fingolimod, is one of the first oral disease-modifying treatments (DMT) that has shown efficacy in advanced clinical trials for the treatment of multiple sclerosis (MS). The present study examined the one-year effectiveness and side effects of fingolimod. Materials and methods: In this quasi-experimental study, 26 MS patients attending Kermanshah Imam Reza Hospital wer...
متن کاملFingolimod therapy for multiple sclerosis.
Because of its potent efficacy and oral route of administration, the approval of fingolimod as treatment for relapsing-remitting multiple sclerosis (MS) was highly anticipated. The therapeutic and adverse effects are mediated by modulation of sphingosine 1-phosphate receptors. Fingolimod inhibits the egress of lymphocytes from lymph nodes and may also have direct effects on the central nervous ...
متن کاملLong-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial.
OBJECTIVE To assess long-term safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (RRMS). METHODS Patients completing FTY720 Research Evaluating Effects of Daily Oral Therapy in MS (FREEDOMS) were eligible for this dose-blinded, parallel-group extension study, continuing fingolimod 0.5 mg/day or 1.25 mg/day, or switching from placebo to either dose, rando...
متن کاملSensory-Neural Hearing Loss as an Early Rebound Relapse after Fingolimod Cessation in Multiple Sclerosis
Introduction: Multiple sclerosis (MS) is a lifelong disease of the brain and spinal cord. Fingolimod is an oral drug which modulates the S1P receptor and is used for relapsing remitting form of MS and can causes rebound activity if it is ceased even in a short period of washout time. Case Report: Here, we introduce a young girl, a known case of MS, who developed revers...
متن کامل